Autonomix Medical Files for Potential $500M Offering

TL;DR

Autonomix Medical is going public, aiming to raise up to $500M. Get ready for a potential ride.

AI Summary

Autonomix Medical, Inc. filed an S-1 form on August 20, 2025, to register for a proposed offering of 10,000,000 shares of common stock. The company, based in The Woodlands, TX, operates in the surgical and medical instruments sector. The filing indicates a potential offering size of up to $500,000,000, with preliminary financial figures showing significant warrant activity and share issuances.

Why It Matters

This S-1 filing signals Autonomix Medical's intent to raise substantial capital through a public offering, which could fund further development and commercialization of its medical technologies.

Risk Assessment

Risk Level: medium — The company is in the early stages of its business, as indicated by the S-1 filing, and faces typical risks associated with medical device development and market entry.

Key Numbers

• 10,000,000 — Shares Offered (Number of common shares proposed for public offering.)
• $500,000,000 — Aggregate Offering Price (Maximum potential capital to be raised from the offering.)
• 0331 — Fiscal Year End (Indicates the company's financial reporting cycle.)

Key Players & Entities

• Autonomix Medical, Inc. (company) — Filer of the S-1 registration statement
• 20250820 (date) — Date of filing
• 10,000,000 (dollar_amount) — Number of common shares proposed to be offered
• $500,000,000 (dollar_amount) — Aggregate offering price of common stock
• The Woodlands, TX (location) — Company's business address

FAQ

Key Financial Figures

• $2.8 million — eds to us of a maximum of approximately $2.8 million; however, we cannot predict when and in
• $1.13 — price of our common stock on Nasdaq was $1.13 per share. There is no established publ
• $15.975 — at a weighted average exercise price of $15.975 per share; 13,500 shares of common sto
• $4.754 — th a weighted average exercise price of $4.754 per share; 370,968 shares available fo
• $6.540 — at a weighted average exercise price of $6.540 per share; 172,262 shares of common st
• $0.001 — at a weighted average exercise price of $0.001 per share; 91,985 shares of common sto
• $10.137 — at a weighted average exercise price of $10.137; and 88,656 shares of common stock und
• $2.671 — at a weighted average exercise price of $2.671. Except as otherwise indicated, the in
• $53.7 million — 2025, we had an accumulated deficit of $53.7 million and working capital of $7.0 million, wh
• $7.0 m — of $53.7 million and working capital of $7.0 million, which raises substantial doubt a

Filing Documents

• amix20250814_s1.htm (S-1) — 2642KB
• ex_854895.htm (EX-5.1) — 12KB
• ex_854827.htm (EX-23.1) — 3KB
• ex_855314.htm (EX-FILING FEES) — 25KB
• a01.jpg (GRAPHIC) — 19KB
• a02.jpg (GRAPHIC) — 23KB
• a03.jpg (GRAPHIC) — 17KB
• a06.jpg (GRAPHIC) — 29KB
• a07.jpg (GRAPHIC) — 18KB
• a08.jpg (GRAPHIC) — 15KB
• amix01.jpg (GRAPHIC) — 3KB
• asllplogo.jpg (GRAPHIC) — 4KB
• 0001437749-25-027461.txt ( ) — 12889KB
• amix-20250630.xsd (EX-101.SCH) — 85KB
• amix-20250630_cal.xml (EX-101.CAL) — 54KB
• amix-20250630_def.xml (EX-101.DEF) — 821KB
• amix-20250630_lab.xml (EX-101.LAB) — 447KB
• amix-20250630_pre.xml (EX-101.PRE) — 856KB
• amix20250814_s1_htm.xml (XML) — 1679KB
• ex_855314_htm.xml (XML) — 5KB

RISK FACTORS

RISK FACTORS 5 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 22

USE OF PROCEEDS

USE OF PROCEEDS 23 DIVIDEND POLICY 23

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 24

BUSINESS

BUSINESS 32 MANAGEMENT 51 EXECUTIVE AND DIRECTOR COMPENSATION 53 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS AND DIRECTOR INDEPENDENCE 59

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 60

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 61 PLAN OF DISTRIBUTION 69 LEGAL MATTERS 70 EXPERTS 70 WHERE YOU CAN FIND MORE INFORMATION 71 INDEX TO FINANCIAL STATEMENTS 72 Table of Contents ABOUT THIS PROSPECTUS This prospectus relates to the resale by the selling shareholders identified in this prospectus under the caption "Selling Shareholders," from time to time, of up to an aggregate of 1,566,252 shares of our common stock issuable upon exercise of our Warrants. We are not selling any shares of our common stock under this prospectus, and we will not receive any proceeds from the sale of shares of common stock offered hereby by the selling shareholders, although we will receive cash from the exercise of the Warrants. You should carefully read this prospectus before deciding to invest in our securities. We have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and

RISK FACTORS

RISK FACTORS Investing in our securities involves a high degree of risk. Before investing in our securities, you should consider carefully the risks and uncertainties discussed hereunder " Risk Factors " . You should carefully consider each of the following risks, together with all other information set forth in this prospectus, including the financial statements and the related notes, before making a decision to buy our securities. If any of the following risks actually occurs, our business could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment. Risks Related to Our Overall Business Factors raise substantial doubt about our ability to continue as a going concern. As of June 30, 2025, we had an accumulated deficit of $53.7 million and working capital of $7.0 million, which raises substantial doubt about our ability to continue as a going concern. Further, we have incurred, and expect to continue to incur, significant costs in pursuit of our business plans. We cannot assure you that our plans to raise sufficient capital to fund our business will be successful. These factors, among others, raise substantial doubt about our ability to continue as a going concern. The financial statements contained elsewhere in this prospectus do not include any adjustments th

View Full Filing

View this S-1 filing on SEC EDGAR